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DEPDC5 Variants Increase Fibrosis Progression in
Europeans With Chronic Hepatitis C Virus Infection
Maria Antonella Burza,1* Benedetta Maria Motta,1* Rosellina Margherita Mancina,1 Piero Pingitore,1
Carlo Pirazzi,1 Saverio Massimo Lepore,2 Rocco Spagnuolo,3 Patrizia Doldo,3 Cristina Russo,2
Veronica Lazzaro,2 Janett Fischer,4 Thomas Berg,4 Alessio Aghemo,5 Cristina Cheroni,6
Raffaele De Francesco,6 Silvia Fargion,7 Massimo Colombo,5,7 Christian Datz,8 Felix Stickel,9
Luca Valenti,7 and Stefano Romeo1,2,10
Chronic hepatitis C virus (HCV) infection may progress to cirrhosis and hepatocellular
carcinoma (HCC). Recently, two genetic variants, DEPDC5 rs1012068 and MICA
rs2596542, were associated with the onset of HCC in Asian subjects with chronic HCV
infection. The aim of the present study was to analyze whether DEPDC5 and MICA
genetic variants were associated with liver disease progression in European subjects with
chronic HCV infection. In a Northern Italian discovery cohort (n 5 477), neither
DEPDC5 rs1012068 nor MICA rs2596542 were associated with HCC (n 5 150). How-
ever, DEPDC5 rs1012068 was independently associated with cirrhosis (n 5 300; P 5
0.049). The association of rs1012068 with moderate to severe fibrosis was confirmed in
an independent cross-sectional German cohort (n 5 415; P 5 0.006). Furthermore,
DEPDC5 rs1012068 predicted faster fibrosis progression in a prospective cohort (n 5
247; P 5 0.027). Next, we examined the distribution of nonsynonymous DEPDC5 var-
iants in the overall cross-sectional cohort (n 5 912). The presence of at least one vari-
ant increased the risk of moderate/severe fibrosis by 54% (P 5 0.040). To understand
the molecular mechanism underlying the genetic association of DEPDC5 variants with
fibrosis progression, we performed in vitro studies on immortalized hepatic stellate cells
(LX-2). In these cells, down-regulation of DEPDC5 resulted in increased expression of
b-catenin and production of its target matrix metallopeptidase 2 (MMP2), a secreted
enzyme involved in fibrosis progression. Conclusion: DEPDC5 variants increase fibrosis
progression in European subjects with chronic HCV infection. Our findings suggest that
DEPDC5 down-regulation may contribute to HCV-related fibrosis by increasing MMP2
synthesis through the b-catenin pathway. (HEPATOLOGY 2016;63:418-427)
C
hronic hepatitis C virus (HCV) infection is
an important health issue affecting approxi-
mately 3% of the population worldwide.1
Although many subjects show only mild or no symp-
toms in the early stages, chronic HCV infection fre-
quently leads to cirrhosis and its complications,
including hepatocellular carcinoma (HCC).2-4 The
progression to cirrhosis and HCC is influenced by
Abbreviations: CI, confidence interval; DEPDC5, DEP domain-containing 5; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; MICA, MHC class I
polypeptide-related sequence A; MMP2, matrix metallopeptidase 2; OR, odds ratio; SMA, smooth muscle actin; TIMP1, tissue inhibitor of metalloproteinase 1;
TIMP2, tissue inhibitor of metalloproteinase 2.
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both environmental (e.g., age, coinfection, alcohol)5-7
and genetic factors.8-13
To date, two studies have examined the susceptibility
to HCC in subjects with chronic HCV infection at a
genome-wide level.14,15 Those two genome-wide associ-
ation studies found that noncoding genetic variants in
the DEP domain-containing 5 (DEPDC5)14 and in the
MHC class I polypeptide-related sequence A (MICA)15
loci confer susceptibility to HCC in Asian subjects with
chronic HCV infection. However, ethnicity influences
the effect of genetic variants.16 Allele frequencies and
haplotype patterns vary considerably, and the effect size
of polymorphisms changes across different popula-
tions.17 Thus, it is important to study whether the effect
of genetic variants may be applied to other populations.
The aim of the study was to examine the effect of
DEPDC5 rs1012068 (T>G), and MICA rs2596542
(C>T) variants on HCC onset in Europeans with
chronic HCV infection.
Subjects and Methods
Study Design. We tested our hypotheses in a dis-
covery cohort (n 5 477) and, subsequently, in inde-
pendent validation cohorts, which comprised a cross-
sectional cohort (n 5 415) and a prospective cohort (n
5 247). Both the discovery and the validation cohorts
consisted of therapy-na€ıve subjects with chronic HCV
infection and no HBVor HIV coinfection. Only the sig-
nificant associations were carried on in the validation
cohorts. Figure 1 illustrates the study design and the
flow of the analyses. To analyze the association between
genetic variants and HCC, we included only patients
with cirrhosis, because cirrhosis is the main risk factor
for HCC.18 To test the association with fibrosis and
maximize the power of our analysis, we compared the
genotype distribution of the DEPDC5 rs1012068 and
MICA rs2596542 variants in the two extremes of fibro-
sis distribution in the discovery cohort: subjects with
no/mild fibrosis (stage F0-F1) versus those with cirrhosis
(i.e., the most severe stage, F4). Next, we validated the
association found with cirrhosis in the cross-sectional
validation cohort and extended it to the full spectrum of
fibrosis. Finally, to confirm our findings in a prospective
way, we analyzed the association between DEPDC5
rs1012068 and fibrosis progression rate (FPR) in the
prospective validation cohort. The analysis of nonsynon-
ymous variants was performed by pooling together the
discovery and the cross-sectional validation cohorts.
Discovery Cohort. The discovery cohort consisted
of 477 subjects with chronic HCV infection enrolled at
Fondazione IRCCS Ca’ Granda Milan, Italy. Subjects
were selected according to the criteria defined above in
the study design from a larger cohort that has been
described previously.19 The degree of liver fibrosis was
assessed histologically according to the METAVIR20
classification. We performed two different analyses by
using two different subsets of this cohort. First, to test
the association between DEPDC5 rs1012068, MICA
rs2596542, and HCC, we analyzed only those subjects
with cirrhosis (n 5 150 with and n 5 150 without
HCC). Next, we examined subjects with no/mild fibro-
sis and those with cirrhosis. No/mild fibrosis was
defined as stage F0-F1 and cirrhosis as stage F4. All sub-
jects gave informed consent to participate in the study,
which was approved by the local ethics committee. The
demographic and clinical characteristics of the discovery
cohort are given in Table 1.
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Validation Cohorts. The validation cohorts con-
sisted of subjects with chronic HCV infection and
included a cross-sectional cohort (n 5 415) and a pro-
spective cohort (n 5 247). The cross-sectional cohort
was created by pooling together a cohort from Bern,
Switzerland, and a cohort from Leipzig, Germany, the
latter of which has been described previously.21 The cur-
rent report includes 268 subjects with chronic HCV
infection and the full spectrum of liver disease. The
Bern cohort included 147 therapy-na€ıve patients with
chronic HCV from Switzerland. The stage of liver fibro-
sis was histologically assessed according to the META-
VIR20 classification. The prospective cohort comprised
247 subjects that were enrolled at the University of
Milan in Milan, Italy. The characteristics of this cohort
have been described in detail previously.22,23 The FPR
was calculated as the ratio between the Ishak score24 and
the disease duration (years) and was considered a contin-
uous variable. The mean disease duration was 25 6 10
years; log10 transformation of FPR was used to obtain
linearity. Ethical approval to include patients for valida-
tion was obtained from all participating institutions,
and all patients signed informed consent to be included
in a genetic analysis. The demographic and clinical char-
acteristics of each discovery cohort are given in Table 1.
Selection of DEPDC5 Nonsynonymous Variants.
By using the Ensembl genome browser,25 we selected all
the DEPDC5 nonsynonymous variants with a minor
allele frequency 1% in Europeans according to 1000
Genomes Project data. We specifically focused on the
nonsynonymous variants because they result in an
amino acidic substitution and likely affect the protein
function. Linkage disequilibrium estimations for the
DEPDC5 variants were examined from the Ensembl
Fig. 1. Study design and flow of the analyses. This picture illustrates
the study design and flow of analyses. Both the discovery and the valida-
tion cohorts consist of therapy-na€ıve subjects with chronic HCV infection.
The discovery cohort consisted of a cross-sectional group of 477 sub-
jects enrolled in Milan (Italy). In the analysis on HCC, only patients with
cirrhosis were included. To test the association with fibrosis, we first ana-
lyzed the extremes of fibrosis distribution (stage F0-F1 versus F4) to max-
imize the power by selecting two extremely different groups. Next, we
examined the association with the full spectrum of fibrosis in the cross-
sectional validation cohort (the Leipzig and Bern cohorts pooled together
[n5 415]) and with fibrosis progression in the prospective cohort (Milan
prospective cohort [n 5 247]). Only the significant associations were
carried on in the validation cohorts. The analysis of nonsynonymous var-
iants was performed by pooling together the discovery and the cross-
sectional validation cohorts.
Table 1. Demographic and Clinical
Characteristics of the Cohorts
Discovery Cohort Validation Cohort
Milan Leipzig Bern
Milan
Prospective
N 477 268 147 247
Age, years 63 6 12 52 6 12 48 6 11 47 6 11
Sex
Men 317 (67) 130 (49) 93 (63) 129 (52)
Women 160 (33) 138 (51) 54 (37) 118 (48)
Alcohol consumption
None/mild* 433 (91) 108 (77) 110 (75) 247 (100)
At-risk† 44 (9) 32 (23)‡ 37 (25) 0 (0)
Liver fibrosis stage
F0-F1 177 (37) 105 (39) 68 (46) 157 (64)
F2-F4 300 (63)§ 163 (61) 79 (54) 90 (36)
Cirrhosis 300 (63) 72 (27) 37 (25) —
HCC 150 (31) 50 (19) 8 (5) 0 (0)
Data are presented as the mean 6 standard deviation or as n (%).
*Defined as 0-20 g/day for women and 30 g/day for men.
†Defined as >20 g/day for women and >30 g/day for men.
‡Data on alcohol intake were not available in 128 subjects (48%).
§All subjects in this cohort had stage F4 fibrosis.
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genome browser data.25 Detailed information on these
variants is reported in Supporting Table 1.
Genotyping of Genetic Variants. The fluorogenic
50-nucleotidase allelic discrimination assay (TaqMan
Applied Biosystems, Foster City, CA) was used to geno-
type all the DEPDC5 variants and MICA rs2596542 in
the discovery and the cross-sectional cohorts according to
the manufacturer’s instructions, with a 95% success
rate. In the prospective validation cohort, DEPDC5
rs1012068 genotyping was performed by Human660W-
Quad BeadChip (Illumina, San Diego, CA), followed by
single-nucleotide polymorphism calling using the default
settings of Genome Studio software. All genotype distri-
butions were in Hardy-Weinberg equilibrium.
Gene Expression. DEPDC5 messenger RNA
(mRNA) expression was assessed in seven immortalized
human cell lines. To assess mRNA expression in cultured
cells, total RNA was isolated from each cell type using an
RNeasy Mini Kit (Qiagen, Valencia, CA). First-strand
complementary DNAs were synthesized from 1 lg RNA
using a reverse-transcription kit (Applied Biosystems).
DEPDC5 and b-catenin mRNA expression were assessed
in LX-2 control cells and in LX-2 DEPDC5 knockout
cells. TaqMan probe and master mix (Life Technologies,
Carlsbad, CA, USA) were used in a total volume of 20
lL per reaction. Real-time polymerase chain reaction
(PCR) assay was performed on a CFX Real-Time PCR
Detection System (Bio-Rad, Hercules, CA). DEPDC5
expression levels were assessed using the delta-delta Ct
method and normalization to b-actin.
DEPDC5 Knockdown. LX-2 cells were transfected
with DEPDC5 small interfering RNA (siRNA) or nega-
tive control (scramble) siRNA (Ambion-Life Technolo-
gies by Thermo Fisher Scientific, Rockford, IL) with
TurboFect Transfection Reagent according to the manu-
facturer’s instructions. The cells were transfected with
25 nM siRNA oligos for 48 hours in serum-free
medium. RNA was isolated from each cell type using an
RNeasy Mini Kit (Qiagen). First-strand complementary
DNAs were synthesized from 1 lg RNA using a reverse-
transcription kit (Applied Biosystems) to confirm
DEPDC5 knockdown.
Cell Proliferation. LX-2 cells were seeded in six-
well plates. When 50% confluent, cells were transfected
with DEPDC5 siRNA or scramble siRNA. Cell num-
bers were counted 24, 48, and 72 hours after transfec-
tion using the Nucleocounter NC-100 (Chemometec
A/S, Lillerød, Denmark).
Immunoblot Analysis. LX-2 cells were seeded in T-
75 plates. When 50% confluent, cells were transfected
with DEPDC5 siRNA or scramble siRNA. Cells were
collected 48 hours after transfection and were lysed in
M-PER Mammalian Protein Extraction Reagent (Pierce,
Thermo Fisher Scientific) containing complete protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, MO).
Immunoblot analysis was performed according to stand-
ard procedures. Bands were visualized using a Chemidoc
XRS System and Image Lab Software (Bio-Rad).
The following antibodies were used: rabbit anti-
collagen I (Sigma-Aldrich), rabbit anti-matrix metallo-
peptidase 2 (MMP2) (Sigma-Aldrich), mouse anti-a-
smooth muscle actin (SMA) (Sigma-Aldrich), rabbit
anti-tissue inhibitor of metalloproteinase 1 (TIMP1)
(Abcam, Cambridge, UK), mouse anti-tissue inhibitor
of metalloproteinase 2 (TIMP2) (Sigma-Aldrich), and
rabbit anti-Calnexin (Abcam).
Statistical Analyses. Data are shown as the mean
and standard deviation or number and proportion. The
distribution of DEPDC5 rs1012068 and MICA
rs2596542 genotypes between the different groups was
compared using Fisher’s exact test. In the analysis of
nonsynonymous variants, we compared the proportion
of subjects with at least one nonsynonymous allele
between subjects with no/mild fibrosis and those with
moderate/severe fibrosis by Fisher’s exact test. Binary
logistic regression was used to evaluate the effect of the
DEPDC5 rs1012068 on severe fibrosis including other
risk factors in the model. The association between
DEPDC5 rs1012068 and FPR was performed by gener-
alized linear model adjusted by age at liver biopsy and
sex. Analyses were performed using IBM SPSS Statistics,
Version 20.0 (IBM, Armonk, NY). DEPDC5 and b-cat-
enin expressions between LX-2 control cells and LX-2
DEPDC5 knockout cells were compared using an inde-
pendent samples Mann-Whitney U test.
Results
DEPDC5 rs1012068 and MICA rs2596542 Are
Not Associated With HCC in Europeans With
Chronic HCV Infection. To examine the association
of DEPDC5 rs1012068 and MICA rs2596452 with
HCC in Europeans, we tested whether the genotype dis-
tribution of these variants was different between patients
with cirrhosis who did or did not also have HCC from
the discovery cohort (n 5 300). We specifically analyzed
only patients with cirrhosis because cirrhosis is the main
risk factor for HCC. We observed no difference in the
DEPDC5 rs1012068 and MICA rs2596542 distribution
between subjects with HCC and those with cirrhosis
(Supporting Table 2). To increase the power of the anal-
ysis, we pooled together the discovery and the cross-
sectional validation cohorts (n 5 403). No difference in
DEPDC5 rs1012068 and MICA rs2596542 distribution
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was observed between subjects with HCC and those with
cirrhosis in the pooled cohort (Supporting Table 2).
DEPDC5 rs1012068, But Not MICA rs2596542,
Is Associated With Cirrhosis. Based on the lack of
association between DEPDC5 rs1012068 and MICA
rs2596542 with HCC, we hypothesized that these two
genetic variants might be associated with fibrosis rather
than HCC. To test this hypothesis and increase the power
to detect the association, we analyzed the association
between DEPDC5 rs1012068 and MICA rs2596542 and
fibrosis by analyzing the extreme stages of fibrosis in the
discovery cohort. Particularly, we compared the genotype
distribution of these genetic variants between subjects
with no/mild fibrosis and those with cirrhosis. Thus,
based on the fibrosis grade defined histologically, we strati-
fied the discovery cohort in subjects with no/mild fibrosis
(n 5 177; stage F0-F1) and those with cirrhosis (n 5
300; stage F4). The prevalence of DEPDC5 rs1012068
was higher in subjects with cirrhosis than in those with
no/mild fibrosis (P 5 0.049; Fig. 2A and Supporting
Table 3). To confirm the association between DEPDC5
rs1012068 and cirrhosis, we analyzed the cross-sectional
validation cohort. We found that the prevalence of
DEPDC5 rs1012068 was higher in subjects with cirrhosis
(F4) than in those with no/mild (F0-F1) fibrosis (P 5
0.006; Fig. 2B and Supporting Table 3). The DEPDC5
rs1012068 G allele was associated with a 40% increased
risk of cirrhosis (odds ratio [OR], 1.40; 95% confidence
interval [CI], 1.08-1.81; P5 0.011; Supplementary Table
4) after adjusting for age, sex, and recruitment center in
the discovery and validation cohorts.
On the contrary, the distribution of MICA
rs2596542 genotypes was not significantly different
according to the presence or absence of cirrhosis (P 5
0.075; Supporting Table 5).
The DEPDC5 rs1012068 Genetic Variant Is Asso-
ciated With Fibrosis Severity in the Validation
Cohorts. To confirm our hypothesis that DEPDC5
rs1012068 variant is associated not only with cirrhosis
but, in general, with a more severe fibrosis, we examined
the cross-sectional validation cohort including subjects
with the entire spectrum of fibrosis. To confirm the asso-
ciation with fibrosis progression, we next analyzed the
prospective validation cohort where the fibrosis progres-
sion rate has been assessed.
First, we examined the cross-sectional cohort and
stratified it in subjects with no/mild fibrosis (n 5 173;
stage F0-F1) and those with moderate/severe fibrosis (n
5 242; stage F2-F4). Consistent with the findings on
cirrhosis, the prevalence of DEPDC5 rs1012068 was
higher in subjects with moderate/severe fibrosis than in
those with no/mild fibrosis (P 5 0.006; Fig. 3A and
Supporting Table 3). DEPDC5 rs1012068 variant was
an independent risk factor for moderate/severe fibrosis
(OR, 1.52; 95% CI, 1.09-2.12; P 5 0.015 per each G
allele; Supporting Table 6) after adjusting for age, sex,
and recruitment center. Results were virtually identical
after adjusting for diabetes and at-risk alcohol intake
(Supporting Table 6).
Next, we tested whether DEPDC5 rs1012068 was
associated with higher FPR in the prospective cohort.
Carriers of this variant had a greater FPR (adjusted P 5
0.027; Fig. 3B and Table 2), independently of age at
liver biopsy and sex.
DEPDC5 Nonsynonymous Variants Confer Sus-
ceptibility to Liver Fibrosis. We next investigated
whether the DEPDC5 gene locus is directly associated
with the development of moderate/severe liver fibrosis.
We examined the distribution of and risk conferred by
DEPDC5 nonsynonymous variants at the onset of
Fig. 2. DEPDC5 rs1012068 is associated with cirrhosis in European subjects with chronic HCV infection. (A) Genotype distribution of DEPDC5
rs1012068 in the discovery cohort. (B) Genotype distribution of DEPDC5 rs1012068 in the cross-sectional validation cohort. The validation
cohort consisted of subjects from the Leipzig and Bern cohorts pooled together. Carriers of the G allele also had a higher risk of cirrhosis (OR,
1.46; 95% CI, 1.04-2.04; P 5 0.027 after pooling together the discovery and the validation cohorts and adjusting for age, sex, and recruitment
center). The exact frequencies are shown in Supporting Table 3.
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moderate/severe fibrosis. The genotype distribution of
the DEPDC5 nonsynonymous variants is shown in Sup-
porting Table 7. To increase the power of our analysis,
we analyzed the discovery and the cross-sectional valida-
tion cohorts pooled together. Specifically, we compared
the presence of DEPDC5 nonsynonymous variants
between subjects with no/mild fibrosis (stage F0-F1)
and those with moderate/severe fibrosis (stage F2-F4).
Subjects with severe fibrosis had a higher, albeit non-
significant (P 5 0.097) prevalence of at least one
DEPDC5 nonsynonymous variants than those with no/
mild fibrosis (67% versus 60%, respectively).
Our analysis of the risk of developing moderate/
severe fibrosis revealed that carriage of at least one non-
synonymous variant was associated with a 54% increase
of the risk of moderate/severe fibrosis (OR, 1.54; 95%
CI, 1.02-2.34; P 5 0.040; Table 3).
DEPDC5 Is Highly Expressed in Immortalized
Hepatic Stellate Cells and Its Knockout Increases b-
catenin Expression and MMP2 Production.
DEPDC5 has a DEP domain involved in several cellular
functions, including the Wnt/b-catenin pathway.26,27
The Wnt/b-catenin pathway is involved in liver fibro-
genesis by affecting hepatic stellate cells activation.28,29
Therefore, to test the hypothesis that DEPDC5
increases fibrosis through this pathway, we first assessed
DEPDC5 expression in seven different human immor-
talized cell types. We found that DEPDC5 is highly
expressed in LX-2 cells, a human hepatic stellate cell line
spontaneously immortalized through culture in low
serum30 (Fig. 4A). Next, to test whether DEPDC5 is
involved in hepatic stellate cell activation through the
Wnt/b-catenin pathway, we incubated LX-2 cells with
and without DEPDC5 siRNA (Ambion) for 48 hours.
DEPDC5 knockdown induces an increase in b-catenin
expression in LX-2 cells (P 5 0.002; Fig. 4B).
Next, we tested the effect of DEPDC5 knockdown
on cell proliferation. Cell numbers were counted 24, 48,
and 72 hours after transfection, and we did not observe
any increase on LX-2 cell proliferation after DEPDC5
knockdown (Supporting Fig. 1).
Furthermore, we tested whether DEPDC5 knock-
down affects the synthesis of molecules involved in liver
fibrogenesis, namely collagen, MMP2, a-SMA, TIMP1,
and TIMP2.30,31 DEPDC5 knockdown resulted in an
increase in MMP2 production (P < 0.05; Fig. 4C,D)
and in no differences in collagen, a-SMA, TIMP1, and
TIMP2 production (Fig. 4C,D).
Fig. 3. DEPDC5 rs1012068 is associated with fibrosis progression in Europeans with chronic HCV infection. The genotype distribution of
DEPDC5 rs1012068 is shown in the cross-sectional (A) and in the prospective (B) validation cohorts. The cross-sectional validation cohort con-
sisted of subjects from Leipzig and Bern cohorts pooled together. Carriers of the G allele also had a higher risk of moderate/severe fibrosis (OR,
1.46; 95% CI, 1.04-2.04; P 5 0.027 after adjusting for age, sex, and recruitment center). The association between DEPDC5 rs1012068 and
FPR was calculated by multivariate generalized linear models under an additive genetic model (see Table 2 for further details).
Table 2. DEPDC5 rs1012068 Is Associated With Higher
Fibrosis Progression Rate in European Subjects With Chronic
HCV Infection
Estimate*
Standard
Error P Estimate†
Standard
Error P
DEPDC5, G alleles 0.078 0.034 0.022 0.074 0.033 0.027
Age at biopsy, years 0.001 0.001 0.54 0.002 0.002 0.31
Sex, men 0.045 0.020 0.026 0.047 0.020 0.020
*Unadjusted.
†Adjusted for age at biopsy and sex.
Table 3. Carriers of DEPDC5 Nonsynonymous Variants Have
Higher Risk of Moderate/Severe Fibrosis
OR 95% CI P
Age, years 1.05 1.04-1.07 <0.001
Sex, men 1.33 0.98-1.81 0.066
Recruitment center 0.88 0.76-1.02 0.095
Nonsynonymous variants 1.54 1.02-2.34 0.040
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Discussion
In this study, we examined the association between
severe liver disease andDEPDC5 rs1012068 in European
subjects with chronic HCV infection. We showed that
DEPDC5 variants confer susceptibility to severe fibrosis.
Genome-wide association studies identified DEPDC5
rs1012068 and MICA rs2596542 as loci of susceptibil-
ity to HCC in Asian subjects with chronic HCV infec-
tion.14,15 In the current study, we examined whether
genotype distribution was different in European subjects
with cirrhosis who did and did not also have HCC. We
examined those two specific groups because HCC
occurs primarily in patients with cirrhosis.18 We found
that neither DEPDC5 rs1012068 nor MICA rs2596542
are associated with HCC in Europeans with chronic
Fig. 4. DEPDC5 is highly expressed in LX-2 cells and DEPDC5 silencing induces b-catenin levels and MMP2 production in LX-2 cells. (A)
DEPDC5 mRNA expression in human tissues assessed by quantitative PCR. The tissue with the highest Ct value was assigned a value of 1. (B)
b-catenin and DEPDC5 mRNA expression in LX-2 cells incubated with negative control (scramble) siRNA or DEPDC5 siRNA for 48 hours. The
experiments were repeated four times. DEPDC5 reduction (P 5 0.001) and b-catenin increase (P 5 0.002) were significant. (C) Lysate fractions
of LX-2 cells transfected with scramble siRNA or DEPDC5 siRNA for 48 hours analyzed by western blotting. Calnexin was used as loading control.
(D) Quantified relative protein levels are shown as column charts. The data are the means 6 standard deviation of four independent experiments
(P < 0.05).
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HCV infection. To understand the discrepancy between
our results and those reported in Asian subjects,14,15 we
analyzed the association between those two variants and
liver fibrosis. To maximize the power of our analysis, we
compared the genotype distribution of the DEPDC5
rs1012068 and MICA rs2596542 variants in the two
extremes of fibrosis distribution: no/mild fibrosis (F0-
F1) versus the most severe stage of fibrosis (F4 [i.e., cir-
rhosis]). We found that MICA rs2596542 was not asso-
ciated with cirrhosis, but we observed an enrichment of
DEPDC5 rs1012068 in subjects with cirrhosis. This
enrichment was confirmed in an independent cross-
sectional validation cohort.
To confirm our hypothesis that the DEPDC5
rs1012068 variant is associated with, in general, a more
severe fibrosis, we examined two validation cohorts: the
cross-sectional and prospective cohorts, which included
subjects with the entire spectrum of fibrosis. In the
cross-sectional cohort, DEPDC5 rs1012068 conferred
an approximately 50% increased risk of fibrosis inde-
pendently of age and sex. This association was con-
firmed in the prospective cohort by observing that
carriers of DEPDC5 rs1012068 had a higher fibrosis
progression rate. Taken together, our data suggest that
DEPDC5 rs1012068 confers susceptibility to the devel-
opment of severe fibrosis, rather than HCC, in Euro-
pean subjects with chronic HCV infection.
The apparent discrepancy between our results and
those reported by the two genome-wide association
studies in Asian subjects14,15 might be due to a key dif-
ference in the study design, as also pointed out by Hosh-
ida et al.32 Cirrhosis, which is the most severe grade of
fibrosis, is the main risk factor for HCC,18 and it is
highly likely that most of the subjects with HCC in the
study by Miki et al.14 had also cirrhosis. However, the
investigators did not use subjects with HCV-related cir-
rhosis without HCC as control group, so it is likely that
the association they found actually refers to severe fibro-
sis rather than to HCC.
Our results are different from those reported by a pre-
vious study in Asian subjects in which DEPDC5
rs1012068 was found to be associated with lower fibro-
sis stage.33 However, that study was conducted only on
a small and selected cohort of subjects who underwent
hepatectomy for HCC. Furthermore, there was no repli-
cation cohort, and the association analysis on fibrosis
was performed differently. On the other hand, our data
are in line with a recent study on HCV-positive subjects
from Saudi Arabia in which homozygotes for DEPDC5
rs1012068 were found to have a 1.7-fold higher risk of
HCV-related cirrhosis.34
The rs1012068 is an intronic variant of DEPDC5,14
and the role of DEPDC5 in hepatic fibrogenesis is cur-
rently unknown. Therefore, to test association of the
DEPDC5 locus with the severity of liver fibrosis by an
independent approach, we examined DEPDC5 nonsy-
nonymous variants. We specifically selected nonsynony-
mous variants because, leading to an amino acidic
change, they are biologically more likely to result in a
functional change of the protein. To increase the power
of our study, we examined whether carriage of at least
one nonsynonymous variant increased the risk of fibrosis
in the pooled cross-sectional discovery and validation
cohort. We found that the presence of nonsynonymous
variants increased the risk of moderate/severe fibrosis,
suggesting that DEPDC5 might be involved in liver
fibrogenesis. A limitation of this analysis is that two of
the nonsynonymous variants are in linkage disequili-
brium (D0 5 1).
DEPDC5 rs1012068 does not affect gene expres-
sion.14 By using the data on linkage disequilibrium
available from Ensembl genome browser, we found that
DEDPC5 rs1012068 is in linkage disequilibrium with
two nonsynonymous variants (rs61731662 and
rs146449468). We therefore speculate that the associa-
tion found for the rs1012068 intronic variant might
mirror the effect of one of these two amino acidic
changes (and possibly others) on the protein structure
and/or function or that this variant is associated with
DEPDC5 expression.
Other DEPDC5 variants have been associated with
familial focal epilepsy,35-37 but the function of the
DEPDC5 protein is still not known. DEPDC5 has a
DEP domain that is involved in different cellular func-
tions, including Wnt signaling.26,27 Wnt/b-catenin sig-
naling is involved in liver fibrogenesis, inducing hepatic
stellate cell activation.28,29 We showed that DEPDC5 is
highly expressed in immortalized LX-2 human hepatic
stellate cells. We also showed that DEPDC5 down-
regulation increases b-catenin expression and induces
MMP2 production in these cells. MMP2 is a down-
stream target of b-catenin.38 In addition, several lines of
evidence suggest that MMP2 is a profibrotic molecule:
(1) it is highly expressed in liver fibrosis,39 (2) it colocal-
izes with activated HSCs,40 (3) it induces a remodeling
of the extracellular matrix in favor of type 1 collagen,41
and (4) it may have an autocrine action inducing HSC
activation.42
We speculate that this noncoding variant, or the
causal variant in linkage with it, determines a reduction
in DEPDC5 expression or activity. This reduction
determines an increase in the Wnt/b-catenin pathway
HEPATOLOGY, Vol. 63, No. 2, 2016 BURZA, MOTTA, ET AL. 425
followed by an increase in the MMP2 synthesis, result-
ing in a higher degree of liver fibrosis.
In conclusion, DEPDC5 variants increase fibrosis
progression in European subjects with chronic HCV
infection. Our findings suggest that DEPDC5 down-
regulation may contribute to HCV-related fibrosis by
increasing MMP2 synthesis trough the b-catenin
pathway.
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